Cyclerion Therapeutics (NASDAQ:CYCN) Releases Earnings Results, Beats Expectations By $16.44 EPS

Cyclerion Therapeutics (NASDAQ:CYCN) issued its earnings results on Tuesday. The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($17.20) by $16.44, Zacks reports. Cyclerion Therapeutics had a negative return on equity of 39.23% and a negative net margin of 170.11%.

Cyclerion Therapeutics Stock Performance

Shares of NASDAQ CYCN traded down $0.05 during trading hours on Wednesday, hitting $3.13. The company’s stock had a trading volume of 4,162 shares, compared to its average volume of 4,165,951. Cyclerion Therapeutics has a 12 month low of $1.03 and a 12 month high of $8.48. The stock has a market cap of $13.57 million, a price-to-earnings ratio of -2.71 and a beta of 1.80. The business has a 50-day simple moving average of $2.59 and a 200-day simple moving average of $1.88.

Institutional Trading of Cyclerion Therapeutics

A hedge fund recently bought a new stake in Cyclerion Therapeutics stock. Two Sigma Investments LP bought a new stake in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned 0.40% of Cyclerion Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 75.62% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded Cyclerion Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, April 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Cyclerion Therapeutics currently has a consensus rating of “Sell”.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.